Sunnyvale, California-based Silk Road says this expands upon the prior launch of its EnRoute system by adding additional configurations. It better tailors the transcarotid artery revascularization (TCAR) procedure to the patient anatomy. TCAR, a minimally invasive procedure, provides stroke protection while minimizing adverse events.
According to a news release, EnRoute marks the only commercially available transcarotid stent system indicated for patients at high risk and standard risk for adverse events from carotid endarterectomy (CEA).
Silk Road Medical designed EnRoute with an optimized cell design. This balances lesion coverage and anatomical conformability for long-term plaque stabilization. The company made it purpose-built for TCAR with a short delivery system …